Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma
Abstract Lung adenocarcinoma (LUAD) is a malignant tumor in the respiratory system. The efficacy of current treatment modalities varies greatly, and individualization is evident. Therefore, finding biomarkers for predicting treatment prognosis and providing reference and guidance for formulating tre...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-08-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-40592-w |
| _version_ | 1797452957603594240 |
|---|---|
| author | Xiang Zhou Ran Xu Tong Lu Chenghao Wang Xiaoyan Chang Bo Peng Zhiping Shen Lingqi Yao Kaiyu Wang Chengyu Xu Jiaxin Shi Ren Zhang Jiaying Zhao Linyou Zhang |
| author_facet | Xiang Zhou Ran Xu Tong Lu Chenghao Wang Xiaoyan Chang Bo Peng Zhiping Shen Lingqi Yao Kaiyu Wang Chengyu Xu Jiaxin Shi Ren Zhang Jiaying Zhao Linyou Zhang |
| author_sort | Xiang Zhou |
| collection | DOAJ |
| description | Abstract Lung adenocarcinoma (LUAD) is a malignant tumor in the respiratory system. The efficacy of current treatment modalities varies greatly, and individualization is evident. Therefore, finding biomarkers for predicting treatment prognosis and providing reference and guidance for formulating treatment options is urgent. Cancer immunotherapy has made distinct progress in the past decades and has a significant effect on LUAD. Immunogenic Cell Death (ICD) can reshape the tumor’s immune microenvironment, contributing to immunotherapy. Thus, exploring ICD biomarkers to construct a prognostic model might help individualized treatments. We used a lung adenocarcinoma (LUAD) dataset to identify ICD-related differentially expressed genes (DEGs). Then, these DEGs were clustered and divided into subgroups. We also performed variance analysis in different dimensions. Further, we established and validated a prognostic model by LASSO Cox regression analysis. The risk score in this model was used to evaluate prognostic differences by survival analysis. The treatment prognosis of various therapies were also predicted. LUAD samples were divided into two subgroups. The ICD-high subgroup was related to an immune-hot phenotype more sensitive to immunotherapy. The prognostic model was constructed based on six ICD-related DEGs. We found that high-risk score patients responded better to immunotherapy. The ICD prognostic model was validated as a standalone factor to evaluate the ICD subtype of individual LUAD patients, which might contribute to more effective therapies. |
| first_indexed | 2024-03-09T15:16:11Z |
| format | Article |
| id | doaj.art-faf64796909742c795d97b6b6c50c38c |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-09T15:16:11Z |
| publishDate | 2023-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-faf64796909742c795d97b6b6c50c38c2023-11-26T13:07:17ZengNature PortfolioScientific Reports2045-23222023-08-0113111510.1038/s41598-023-40592-wImmunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinomaXiang Zhou0Ran Xu1Tong Lu2Chenghao Wang3Xiaoyan Chang4Bo Peng5Zhiping Shen6Lingqi Yao7Kaiyu Wang8Chengyu Xu9Jiaxin Shi10Ren Zhang11Jiaying Zhao12Linyou Zhang13Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical UniversityAbstract Lung adenocarcinoma (LUAD) is a malignant tumor in the respiratory system. The efficacy of current treatment modalities varies greatly, and individualization is evident. Therefore, finding biomarkers for predicting treatment prognosis and providing reference and guidance for formulating treatment options is urgent. Cancer immunotherapy has made distinct progress in the past decades and has a significant effect on LUAD. Immunogenic Cell Death (ICD) can reshape the tumor’s immune microenvironment, contributing to immunotherapy. Thus, exploring ICD biomarkers to construct a prognostic model might help individualized treatments. We used a lung adenocarcinoma (LUAD) dataset to identify ICD-related differentially expressed genes (DEGs). Then, these DEGs were clustered and divided into subgroups. We also performed variance analysis in different dimensions. Further, we established and validated a prognostic model by LASSO Cox regression analysis. The risk score in this model was used to evaluate prognostic differences by survival analysis. The treatment prognosis of various therapies were also predicted. LUAD samples were divided into two subgroups. The ICD-high subgroup was related to an immune-hot phenotype more sensitive to immunotherapy. The prognostic model was constructed based on six ICD-related DEGs. We found that high-risk score patients responded better to immunotherapy. The ICD prognostic model was validated as a standalone factor to evaluate the ICD subtype of individual LUAD patients, which might contribute to more effective therapies.https://doi.org/10.1038/s41598-023-40592-w |
| spellingShingle | Xiang Zhou Ran Xu Tong Lu Chenghao Wang Xiaoyan Chang Bo Peng Zhiping Shen Lingqi Yao Kaiyu Wang Chengyu Xu Jiaxin Shi Ren Zhang Jiaying Zhao Linyou Zhang Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma Scientific Reports |
| title | Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma |
| title_full | Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma |
| title_fullStr | Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma |
| title_full_unstemmed | Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma |
| title_short | Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma |
| title_sort | immunogenic cell death based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma |
| url | https://doi.org/10.1038/s41598-023-40592-w |
| work_keys_str_mv | AT xiangzhou immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT ranxu immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT tonglu immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT chenghaowang immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT xiaoyanchang immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT bopeng immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT zhipingshen immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT lingqiyao immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT kaiyuwang immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT chengyuxu immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT jiaxinshi immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT renzhang immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT jiayingzhao immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma AT linyouzhang immunogeniccelldeathbasedprognosticmodelforpredictingtheresponsetoimmunotherapyandcommontherapyinlungadenocarcinoma |